ZFP36 and prostate adenocarcinoma: To model the clinical finding that low expression of ZFP36 synergizes with PTEN loss to drive aggressive PCa progression, we engineered Zfp36 deletion in a previously characterized mouse model of prostate adenocarcinoma induced by Pten deletion (37).